Q4 2024 Vistagen Therapeutics Inc Earnings Call Transcript
Key Points
- Positive results from the PALISADE-2 US Phase 3 study of fasedienol for the acute treatment of social anxiety disorder (SAD).
- Launch of the PALISADE-3 Phase 3 trial, marking a significant step forward in the registration-directed PALISADE Phase 3 program for fasedienol in SAD.
- Favorable and differentiated safety profiles demonstrated by the non-systemic, neurocircuitry-focused pherines in all clinical studies completed to date.
- Significant decrease in research and development expenses from $44.4 million in 2023 to $20 million in 2024.
- Strong cash position with $119.2 million in cash and cash equivalents as of March 31, 2024.
- No specific guidance provided on enrollment numbers or screen failure rates for the PALISADE-3 trial.
- General and administrative expenses remained relatively high at $14.1 million for the year ended March 31, 2024.
- Net loss attributable to common stockholders was $29.4 million for the year ended March 31, 2024.
- Potential variability in the public speaking challenge protocol and the need for enhanced surveillance and control measures.
- Uncertainty around the outcomes of the repeat dose study and its impact on labeling and safety data.
Greetings and welcome to the Vistagen Therapeutics fiscal year-end 2024 corporate update conference call. (Operator Instructions) As a reminder, this conference is being recorded. I would now like to turn the conference over to your host, Mark McPartland, Senior Vice President of Investor Relations.
Thank you, Joe. Good afternoon, everyone, and welcome to Vistagen's fiscal year-end 2024 corporate update conference call and webcast. This afternoon, we filed our annual report with the Securities and Exchange Commission or SEC, on SEC Form 10-K for our fiscal year ended March 31, 2024, and issued a press release provide an overview of our progress during our fiscal year 2024. We encourage you to review the press release and our 10-K, both of which can be found in the Investors section of our website.
During today's call, we'll make forward-looking statements regarding our business based on our current expectations and information. These forward-looking statements speak
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
